Respiratory syncytial virus

Real-World Effectiveness of Nirsevimab: Evidence from the NIRSE-GAL Study

The NIRSE-GAL study is an ongoing population-based, prospective, longitudinal study conducted in Galicia, Spain. It includes infants eligible to receive nirsevimab and evaluates its impact on RSV-related outcomes in both inpatient and outpatient healthcare settings.

Expanding RSV Protection in Kuwait: New National Directives for Monoclonal Antibody Use

Summary of Kuwait’s updated RSV prevention policy

Healthcare Utilization and Economic Burden of RSV Infections Among Children Under 5 Years in Saudi Arabia: A MNGHA Facilities Analysis

Nirsevimab FAQs

RWE data on Nirsevimab and RSV preF vaccine

Real‑world evidence (RWE) provides valuable insights into the effectiveness, safety, and use of RSV preventive strategies beyond clinical trials. This data support informed decision‑making and optimize the implementation of RSV prevention strategies in real‑world settings

Ensuring overall RSV prevention in every individual Dr. Alia Podcast

Kuwait taking the lead in RSV protection for all infants in the Middle east

Podcast Dr. Dana Hajan

Nirsevimab RWD Metanalysis

Nirsevimab Metanalysis Real world data

RSV Burden in Jazan

Beyond High-Risk: Expanding RSV Protection for Newborns and Infants

New horizon of RSV lower respiratory tract disease LRTD in infants: Reflection on two seasons of prevention

Burden of Disease

RSV History

RSV

All Infant Protection

RSV Burden in Infants

Rattle

Implementing Beyfortus successfully

Saudi initiatives on Bronchiolitis Recommendations

The first choice of RSV prevention is Nirsevimab; alternatively, palivizumab is to be considered in case of unavailability of Nirsevimab.